Platform technology

#17

Development of novel methods for identifying disease markers using in vitro disease model cells

Identification of specific disease markers is very useful for the "early detection" of diseases. In recent years, the application of genome editing technology and disease-specific iPS cells enabled the generation of cell lines that reflect many pathological conditions.  Therefore, these cell lines may be useful as a new approach for identifying disease markers.

In this category, Takeda is seeking exploring research for disease markers and the proposal of a method of verification using disease model cells regardless of the pathology type. The areas of interest include but are not limited to:

  • A method for searching and analyzing candidate molecules useful as disease markers.
  • Validation method of selected candidate molecules in clinical samples.



#18

Methods for inducing highly efficient differentiation of human iPSCs into parvalbumin interneurons

Dysfunction of parvalbumin (PV) interneurons is one of the key factors to induce cognitive impairment in psychiatry disorders (e.g. schizophrenia, autism spectrum disorder). Human induced pluripotent stem cells (hiPSC)-derived neurons are widely used because they can be derived from patients' cells. On the other hand, there are still issues regarding purity and maturation in generation of hiPSC-derived PV interneurons. Here, we would like to recruit projects that aim to establish high efficient differentiation method of human iPSC-derived parvalbumin interneurons.



#19

Disease model construction and mechanism analysis of neurological disorders using human iPS cells and primary cells

Many familial type mutations have been identified in neurological disorders. In some cases of familial type mutations, the penetrance rate is about 100%. But, there are a few cases of asymptomatic carriers who do not develop diseases. We are looking for the project identifying novel compensatory mechanisms against disease development by analyzing rare asymptomatic carriers with clinical samples such as blood cells and iPS cells of them and their relatives.

Areas of interest:

  • Mood disorders, Schizophrenia, Autism spectrum disorders, PTSD
  • Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, ALS



#20

Platform research of organoids for analysis of higher brain function and disease mechanism

Neuronal/Brain organoids have the potential to become highly translatable disease models. We are seeking a phenotypic screening system by leveraging organoid technology to conduct patient-centric drug discovery for neurodegenerative diseases. To pursue this opportunity, we are also focusing on the improvement of organoid generation technologies and that of functional analysis technologies. We call for ideas regarding Neuronal/Brain organoid research:

  • Assay system to detect abnormality of axonal transports associated with dementia in human iPSC-derived neuronal cells and/or brain organoids.
  • Bioengineering techniques to accelerate the generation of human 3D cortical brain organoids with spatially defined structure.
  • Platform technology for detecting the neural function and network on 3D human brain organoid and/or acute brain tissue under culture conditions.



#21

Target identification and biomarker analysis by single cell proteomics

Target identification and biomarker discovery are important steps for phenotypic assay based drug development. For those activities, proteomics analysis is a powerful tool, however, conventional proteomics analysis uses more than sub mg of total protein (1x10^6 cells~) as material. Because of that, it requires a lot of time and cost especially when the targeting materials are iPS cells or extracellular vesicles such as exosomes that are hard to prepare in a large scale. Here we seek technology that enables ultra-high sensitive proteomics analysis, such as single-cell proteomics, to achieve the target identification and biomarker analysis with trace amount of biological materials.



#22

Nucleic acid medicine platform with new concepts

Nucleic acid medicine such as an antisense oligonucleotide, siRNA, and aptamer is well known as a new modality which could target "undruggable target" for conventional drug modalities (i.e. small molecules, mAb, etc.) We expect the innovative idea with novel mechanism of action and technology platform leading to oligonucleotide therapeutics.



#23

Development of a novel technology platform for the delivery of oligonucleotide therapeutics to specific neuronal cells (neuron, microglia, astrocyte etc.) in brains.

Recently, application of oligonucleotide therapeutics to neuropsychiatric disorders is highly anticipated. However, oligonucleotides cannot cross  the blood-brain barrier, which is a big hurdle for the development of nucleic acid medicine. Thus, a platform which can effectively deliver oligonucleotide into brain, especially to specific brain cells such as neuron, microglia and astrocytes, is needed. We expect the innovative idea on technology platform to overcome these challenges.



#24

Chemistry-driven novel technologies, methods or ideas that lead to breakthroughs in neuroscience drug discovery

We are recruiting research themes to bring about breakthroughs in neuroscience drug discovery, including, but not limited to, the following examples.

  • Drug discovery research on tough targets
    (e.g.) biased- or heterodimer-selective GPCR ligands, allosteric ligands, phosphatase inhibitors, and protein-protein interaction modulators

  • Drug discovery research based on innovative mechanism of action
    (e.g.) protein degradation inducers, ligands acting on RNAs (incl. splicing modulators), and small molecule chemical chaperones

  • Research on brain-targeted drug delivery technologies and evaluation of their mechanisms of action
  • Development of in vitro / in vivo imaging probes
  • Exploration of novel drug targets or biomarkers based on big data



#25

Chemistry-driven novel technologies, methods or ideas to accelerate drug discovery with new modalities (peptides, antibodies, nucleic acids, cell therapy, etc.)

We are recruiting research themes to combat issues in drug discovery using new modalities, including, but not limited to, the following examples.

  • Investigation of technologies for the improvement of biodistribution of antisense oligonucleotides and siRNA
  • Research on Structure-Activity/Toxicity-Relationship in oligonucleotide drug discovery based on 3D structural analysis
  • Research on tissue- and/or cell-targeting drug delivery technologies and evaluation system of their mechanisms of action
  • Investigation into convenient chemical and/or biological methods of glycan preparation for research into glycobiology and glycotechnology
  • Research on therapeutic modalities such as regenerative medicine and cell therapy using synthetic compounds



#26

Chemistry-driven novel technologies, methods or ideas to improve and/or optimize the drug discovery process

We are recruiting research themes to improve and/or accelerate the drug discovery process, including, but not limited to, the following examples. 

  • Development of novel drug discovery algorithms based on artificial intelligence and/or molecular simulation
    (e.g.) pharmacological activity and/or adverse effect prediction, and design of novel compounds

  • Drug discovery research based on phenotypic screening
    (e.g.) innovative technologies for cellular high throughput screening, novel methods for target identification, and novel methods for compound optimization (incl. methods toward small molecules from hits with medium/high molecular weight, such as natural compounds)

  • Development of technologies to create next generation diverse compound libraries
  • Development of nano-scale organic synthesis technologies



Other Areas of Interest




How to Apply

Follow the procedure below to make an application.

  1. Download the Proposal Sheet below, and complete based on the non-confidential information.

  2. Click "SUBMIT". To proceed with the application you must agree with the Terms and Conditions that are presented to you. Once you have agreed with them, click “I ACCEPT”.

  3. Complete the Application Form with your Proposal Sheet prepared at Step1 attached, and click "SUBMIT".

  4.  After submission, your website will show the “Submission Completed” page and you will receive a confirmation email.

CONTACT

Please contact the COCKPI-T® Funding Office for further information.

COCKPI-T@takeda.co.jp

  

* Please be aware that we may not be able to respond to every inquiry.